Citius Story

<div class='circular--portrait' style='background:#82ADFD;color: #ffffff;font-size:4em;'>CP</div>
CTXR -- USA Stock  

USD 2.03  0.03  1.46%

Citius Pharmaceuticals Issuance Repayment of Debt Securities is relatively stable at the moment as compared to the past year. Citius Pharmaceuticals reported last year Issuance Repayment of Debt Securities of 1.13 Million. As of 02/20/2021, Net Cash Flow from Financing is likely to grow to about 1.1 M, while Earnings Before Interest Taxes and Depreciation Amortization EBITDA are likely to drop (1.3 M). Today's short post will sum up Citius Pharmaceuticals as your potential position. We will discuss the question of why retail investors should continue to be confident in Citius Pharmaceuticals outlook.
Published six days ago
View all stories for Citius Pharmaceuticals | View All Stories
Our latest forecast of Citius (NASDAQ:CTXR)
Citius Pharmaceuticals is UNDERVALUED at 2.69 per share with modest projections ahead. About 22.0% of Citius Pharmaceuticals shares are held by company insiders. Insiders ownership of Citius Pharmaceuticals refers to the amount of Citius Pharmaceuticals equity owned by Citius officers, directors, relatives of the leadership team, or anyone who has access to private information before it's made available to the public. Check out our latest analysis of Citius, including its current ownership diagnostics.
There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as Citius Pharmaceuticals. Regardless of method or technology, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.

Predictive Modules for Citius Pharmaceuticals

Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Citius Pharmaceuticals' stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Citius Pharmaceuticals in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Citius Pharmaceuticals. Your research has to be compared to or analyzed against Citius Pharmaceuticals' peers to derive any actionable benefits. When done correctly, Citius Pharmaceuticals' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Citius Pharmaceuticals.

How important is Citius Pharmaceuticals's Liquidity

Citius Pharmaceuticals financial leverage refers to using borrowed capital as a funding source to finance Citius Pharmaceuticals ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Citius Pharmaceuticals financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Citius Pharmaceuticals's total debt and its cash.

How Citius utilizes its cash?

To perform a cash flow analysis of Citius Pharmaceuticals, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Citius Pharmaceuticals is receiving and how much cash it distributes out in a given period. The Citius Pharmaceuticals cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Citius Pharmaceuticals Net Cash Flow from Operations is relatively stable at the moment as compared to the past year. Citius Pharmaceuticals reported last year Net Cash Flow from Operations of (1.1 Million)

Detailed Outlook On Citius Pharmaceuticals

Citius Pharmaceuticals is displaying above-average volatility over the selected time horizon. Investors should scrutinize Citius Pharmaceuticals independently to ensure intended market timing strategies are aligned with expectations about Citius Pharmaceuticals volatility.

Returns Breakdown

Return on Assets(0.65)
Return on Equity(0.62)
Return Capital(0.89)

Another 3 percent spike for Citius Pharmaceuticals

The semi deviation is down to 3.23 as of today. As of the 20th of February, Citius Pharmaceuticals shows the Mean Deviation of 4.08, downside deviation of 4.42, and Risk Adjusted Performance of 0.1565. Citius Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We are able to break down and analyze data for nineteen technical drivers for Citius Pharmaceuticals, which can be compared to its rivals. Please confirm Citius Pharmaceuticals variance and potential upside to decide if Citius Pharmaceuticals is priced correctly, providing market reflects its regular price of 2.06 per share. Please also double-check Citius Pharmaceuticals total risk alpha, which is currently at 0.4657 to validate the company can sustain itself at a future point.

The Current Takeaway on Citius Pharmaceuticals Investment

While some other firms under the biotechnology industry are still a bit expensive, Citius Pharmaceuticals may offer a potential longer-term growth to retail investors. While some retail investors may not share our view we believe that the current risk-reward utility is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Citius Pharmaceuticals.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Citius Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to